Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance
- 10 April 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1687-1700
Abstract
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be limited by graft-versus-host disease (GVHD). T-cell activation is a key factor in GVHD progression. Costimulatory signals can be counterbalanced by coinhibitory signals such as the checkpoint molecule VISTA (V-domain immunoglobulin-containing suppressor of T-cell activation)/programmed death-1 homolog that restrains activation and maintains donor T-cell quiescence. A single dose of anti-VISTA monoclonal antibody (mAb) prevents acute GVHD lethality in multiple models. Naïve donor T cells express moderate VISTA levels, which transiently increase in allo-HSCT recipients in association with T-cell receptor signaling, leading to heightened susceptibility to anti-VISTA mAb–mediated depletion, in contrast to donor T cells transferred to syngeneic recipients. Anti-VISTA mAb donor T-cell depletion was compatible with rapamycin but incompatible with peritransplant tacrolimus GVHD prophylaxis. Targeting VISTA exclusively on host cells or donor CD8+ T cells was not protective against GVHD lethality. Instead, anti-VISTA mAb–mediated deletion of alloreactive donor T cells depended on targeting a third (non-T) cell type. Further mechanistic studies indicated that donor T cells concurrently exposed to anti-VISTA mAb in vivo but not preincubated in vitro before adoptive T-cell transfer were eliminated via Fc receptor (FcR)-mediated phagocytosis. In a lymphoma challenge model, a graft-versus-lymphoma (GVL) effect was fully retained when anti-human VISTA mAb exclusively targeted donor CD4+ T cells, and was delayed but mostly retained when unseparated donor T cells were infused. In a xenogeneic GVHD model, anti-human VISTA mAb reduced donor T-cell expansion, VISTA T-cell expression levels, and recipient lethality. Together, these data support a novel clinical translational pathway in which acute GVHD lethality can be mitigated without negating the GVL effect.Keywords
This publication has 43 references indexed in Scilit:
- VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanismsCell Reports, 2024
- Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisNew England Journal of Medicine, 2023
- A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndromeThe FASEB Journal, 2020
- VISTA: A novel immunotherapy target for normalizing innate and adaptive immunitySeminars in Immunology, 2019
- Acute Graft-versus-Host Disease — Biologic Process, Prevention, and TherapyNew England Journal of Medicine, 2017
- The influences of age on T lymphocyte subsets in C57BL/6 miceSaudi Journal of Biological Sciences, 2017
- Recruitment of calcineurin to the TCR positively regulates T cell activationNature Immunology, 2016
- T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouseJournal of Experimental Medicine, 2011
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantationBone Marrow Transplantation, 2004